Pseudomyxoma Peritonei Centre, Basingstoke and North Hampshire Hospital Foundation Trust, Aldermaston Road, Basingstoke, Hampshire RG24 9NA, UK.
Eur J Surg Oncol. 2010 Dec;36(12):1156-61. doi: 10.1016/j.ejso.2010.09.004. Epub 2010 Sep 22.
Pseudomyxoma peritonei (PMP) is characterized by mucinous ascites, predominantly arising form a perforated tumour of the appendix. This study aimed to assess Health-Related Quality of Life (HRQL) in patients following cytoreductive surgery and intraperitoneal chemotherapy for PMP.
Over a one year period, 49 consecutive patients (13 male, 36 females) with a median age of 55 (range 37-81 years) were enrolled. Patients were asked to complete the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire prior to surgery and at one, three, six and twelve months post-operatively.
26 patients (53%) underwent complete cytoreduction and 20 (42%) patients had major tumour debulking. One patient died from progressive disease three months from surgery and two patients withdrew from the study within 6 months of surgery. Baseline questionnaire compliance was 100 per cent and remained high (overall 98% of eligible patients) during follow up. Grade III/IV morbidity occurred in 4 patients (9%). Patients undergoing both complete cytoreduction and major tumour debulking reported a clinically significant improvement in emotional well-being, appetite and global HRQL at 1 year following surgery.
Despite the high morbidity associated with cytoreductive surgery and intraperitoneal chemotherapy, an improvement in quality of life at 1 year following the procedure was seen following both complete cytoreduction and major tumour debulking. Longer term assessment is required to demonstrate the durability of this enhancement.
假性黏液瘤（PMP）的特征是黏液性腹水，主要由阑尾穿孔肿瘤引起。本研究旨在评估接受细胞减灭术和腹腔内化疗的 PMP 患者的健康相关生活质量（HRQL）。
在一年的时间里，共纳入了 49 名连续患者（男性 13 名，女性 36 名），中位年龄为 55 岁（范围 37-81 岁）。患者在手术前和手术后 1、3、6 和 12 个月被要求完成欧洲癌症研究与治疗组织（EORTC）的 QLQ-C30 问卷。
26 名患者（53%）接受了完全细胞减灭术，20 名患者（42%）接受了主要肿瘤切除术。一名患者在手术后三个月因疾病进展死亡，两名患者在手术后 6 个月内退出了研究。基线问卷的依从率为 100%，在随访期间仍保持较高水平（总共有 98%的合格患者）。4 名患者（9%）出现 III/IV 级发病率。接受完全细胞减灭术和主要肿瘤切除术的患者在手术后 1 年报告情绪健康、食欲和总体 HRQL 有显著改善。
尽管细胞减灭术和腹腔内化疗相关的发病率较高，但在手术 1 年后，完全细胞减灭术和主要肿瘤切除术都能改善生活质量。需要更长期的评估来证明这种改善的持久性。
